The metabolic reprogramming of T cells controls airway remodeling in severe asthma

This study identifies that metabolic reprogramming of Th17 cells via the OXPHOS pathway drives LIGHT-mediated airway remodeling in severe mixed granulocytic asthma, demonstrating that dual blockade of OXPHOS and LIGHT effectively reverses disease features and restores regulatory T cell numbers.

The Gist

The Big Picture: A Stubborn House Fire

Imagine your lungs are a house. In severe asthma (specifically a type called Mixed Granulocytic Asthma, or MGA), the house isn't just having a small fire; it's undergoing a chaotic renovation that turns the cozy living room into a concrete bunker.

Normally, asthma is like a fire caused by dust mites (allergens) that the body tries to put out with "firefighters" called Th2 cells. Standard asthma medicines (like steroid inhalers) work great on these firefighters—they calm them down and stop the fire.

But in severe asthma, the body switches tactics. Instead of Th2 firefighters, it sends in a different, much tougher crew: Th17 cells. These cells are like a construction crew that doesn't just fight the fire; they start building thick, hard walls (fibrosis/remodeling) inside the airways. This makes breathing difficult and, crucially, standard steroids don't work on them. The fire keeps burning, and the walls keep getting thicker.

The Culprits: The "Engine" and the "Foreman"

The researchers discovered two specific things driving this stubborn construction crew:

1. The Engine (OXPHOS): Think of Th17 cells as high-performance race cars. To run fast and survive, they need a super-efficient engine. In this disease, the Th17 cells switch their fuel source to a high-powered engine called OXPHOS (Oxidative Phosphorylation). This engine gives them the energy to survive attacks (like steroids) and keep building those thick walls.
2. The Foreman (LIGHT): Once the engine is running, the Th17 cells send out a signal called LIGHT. Imagine LIGHT as the foreman shouting orders to the construction site. The foreman tells the lung tissue, "Build more walls! Make the airways narrower!" This signal triggers the actual scarring and hardening of the lungs.

The Discovery: How They Work Together

The paper explains a vicious cycle:

• The Engine (OXPHOS) keeps the Th17 cells alive and angry.
• The Foreman (LIGHT) tells the lungs to remodel and scar.
• Together, they create a "perfect storm" of severe, steroid-resistant asthma.

The researchers also found that when you treat the Th2 cells with steroids, the Th2 cells die off, but the Th17 cells (with their super-charged engines) actually take over the whole neighborhood. This explains why some patients get worse on steroids—the "good" firefighters are gone, leaving only the "bad" construction crew.

The Solution: Cutting the Power and Silencing the Foreman

The team tested a new strategy: Dual Blockade. Instead of just trying to calm the inflammation, they tried to stop the construction crew at its source.

1. Turn off the Engine: They used a drug to inhibit OXPHOS. This is like cutting the fuel line to the race cars. Without this high-powered engine, the Th17 cells lose their super-strength, stop multiplying, and eventually die off.
2. Silence the Foreman: They used a blocker to stop the LIGHT signal. This is like taking the megaphane away from the foreman. Even if a few construction workers are left, they can't shout orders to build more walls.

The Result?
When they used both methods together in mice, the magic happened:

• The thick walls (fibrosis) started to dissolve.
• The airways opened up again.
• The "bad" construction crew (Th17) vanished.
• Surprisingly, the "good" peacekeepers (T-regulatory cells) came back to restore order.

Why This Matters for Humans

The researchers looked at data from humans with severe asthma, as well as other diseases like rheumatoid arthritis, psoriasis, and multiple sclerosis. They found that in all these conditions, the same "Engine" and "Foreman" are active.

The Takeaway:
Current treatments often try to put out the fire (inflammation), but in severe asthma, the problem is the construction (scarring). This paper suggests that to fix severe asthma, we need to kill the engine that powers the stubborn cells and silence the foreman that orders the scarring. By doing both, we might finally be able to reverse the damage and help patients breathe freely again.

It's like realizing that to fix a house that's being turned into a bunker, you don't just yell at the workers; you cut their power supply and take away their blueprints.

Technical Summary

1. Problem Statement

Severe asthma, specifically the Mixed Granulocytic Asthma (MGA) endotype, represents a significant public health burden. MGA is characterized by:

• A Th2-low phenotype (low eosinophils/IL-13) but high Th17/neutrophilic inflammation.
• Exacerbated airway remodeling (fibrosis, smooth muscle hypertrophy).
• Resistance to standard treatments, including inhaled corticosteroids (ICS) and anti-IL-17 therapies.

Current clinical trials targeting Th2 cytokines or IL-17 directly have failed to treat severe MGA effectively. There is a critical knowledge gap regarding:

1. How Th17 cells drive pathological tissue remodeling independently of IL-17.
2. The metabolic mechanisms driving Th17 differentiation and survival in MGA.
3. The specific signaling pathways linking Th17 cells to fibrosis.

2. Methodology

The authors employed a multi-faceted approach combining in vivo mouse modeling, in vitro cellular assays, transcriptomics, and human data re-analysis.

• Mouse Model Generation:
  • Used Il4rα-/- mice (defective IL-4/IL-13 signaling) challenged with House Dust Mite (HDM) to mimic the human Th2-low/MGA phenotype.
  • Compared against wild-type (WT) Balb/c mice (Th2/Eosinophilic Asthma model).
• Intervention Strategies:
  • T-cell Depletion: Anti-CD4/CD8 antibodies to establish T-cell dependency.
  • Cell Transfer: Sorted Th2 (from WT) and Th17 (from Il4rα-/-) cells transferred into Rag1-/- or Il4rα-/-Tnfsf14-/- hosts.
  • Pharmacological Inhibition:
    • OXPHOS Inhibition: IACS-010759 (Complex I inhibitor).
    • LIGHT Signaling Blockade: LTβR-Fc (antagonistic reagent).
    • Steroid/Anti-IL17: Dexamethasone and anti-IL-17A antibodies.
  • Genetic Models: Used Mmp9-/-, Tnfsf14-/- (LIGHT-/-), and Il4rα-/-Tnfsf14-/- mice.
• Metabolic & Molecular Assays:
  • Seahorse XF Analysis: Measured Oxygen Consumption Rate (OCR) to assess mitochondrial OXPHOS activity.
  • In Vitro Polarization: T cells polarized in glucose (glycolysis) vs. galactose (OXPHOS) media with/without inhibitors.
  • Co-cultures: Fibroblasts co-cultured with Th17 cells to assess activation (α-SMA expression).
• Omics & Human Data:
  • RNA-seq: Performed on sorted lung cell populations (T cells, neutrophils, eosinophils, macrophages, stromal cells).
  • Public Data Re-analysis: Analyzed GEO datasets (GSE89809, GSE137268, GSE76262) from human severe asthmatics and other fibrotic diseases (IPF, COPD, RA, MS, etc.).
• Readouts: Airway hyperresponsiveness (AHR), flow cytometry (cell counts), histology (Masson's Trichrome, H&E, α-SMA, MMP9, OPN staining), and qPCR.

3. Key Contributions

1. Novel Mouse Model: Validated the Il4rα-/- HDM model as a robust recapitulation of human MGA, featuring steroid resistance, Th17/neutrophilic dominance, and severe fibrosis.
2. Metabolic Mechanism: Identified Mitochondrial OXPHOS as the critical driver of pathogenic Th17 cell survival and differentiation in MGA, distinct from glycolytic Th2 cells.
3. LIGHT as the Fibrotic Effector: Established that LIGHT (TNFSF14) produced by Th17 cells is the primary driver of airway remodeling, acting via the MMP9-TGFβ axis.
4. Therapeutic Synergy: Demonstrated that while monotherapies (OXPHOS inhibition or LIGHT blockade) partially improve disease, dual blockade is required to completely reverse fibrosis, neutrophilia, and AHR while restoring Treg populations.

4. Key Results

• Model Validation: Il4rα-/- mice exposed to HDM developed severe MGA with high Th17 cells, neutrophils, and airway remodeling. These mice were resistant to dexamethasone and anti-IL-17 therapy, unlike WT mice.
• T-Cell Dependency: Depletion of T cells abolished airway remodeling and neutrophilia. Transfer of Th17 cells (but not Th2 cells) into naïve hosts induced significant fibrosis.
• OXPHOS Enrichment:
  • RNA-seq revealed OXPHOS gene signatures were enriched specifically in T cells (not other immune cells) in MGA lungs.
  • Seahorse assays confirmed higher oxygen consumption rates in MGA T cells.
  • Mechanism: OXPHOS inhibition reduced RORγt expression and Th17 differentiation. It also induced apoptosis in Th17 cells cultured in galactose (OXPHOS-dependent), whereas Th1/Th2 cells remained unaffected.
  • Steroid Resistance: Dexamethasone treatment in vitro skewed Th2 cells toward a Th17 phenotype (downregulating GATA3, upregulating RORγt), explaining the clinical shift to Th2-low/MGA in steroid-treated patients.
• LIGHT and Remodeling:
  • LIGHT expression was significantly elevated in MGA mice and human MGA patients.
  • Mechanism: LIGHT stimulates bronchial epithelial cells to produce MMP9. MMP9 cleaves latent TGFβ, activating the fibrotic pathway.
  • Genetic Proof: Mmp9-/- mice were protected from LIGHT-induced remodeling. Tnfsf14-/- (LIGHT-/-) mice showed reduced remodeling.
• OPN and Fibroblast Activation: OXPHOS-high Th17 cells upregulated Osteopontin (OPN), which directly activates fibroblasts (increasing α-SMA). This OPN production was partially dependent on LIGHT.
• Dual Blockade Efficacy:
  • OXPHOS Inhibition alone: Reduced Th17 cells and neutrophils but failed to reverse pre-formed collagen.
  • LIGHT Blockade alone: Reduced fibrosis but did not kill Th17 cells (risk of recurrence).
  • Combined Therapy: Simultaneous blockade of OXPHOS and LIGHT completely reversed all disease features (fibrosis, AHR, neutrophilia) and significantly increased Foxp3+ Treg cells, restoring immune balance.
• Broad Relevance: The LIGHT/OXPHOS signature was found elevated in multiple human Th17-driven fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF), COPD, Rheumatoid Arthritis, Psoriasis, and Multiple Sclerosis.

5. Significance

This study fundamentally shifts the understanding of severe asthma from a purely inflammatory disorder to a metabolic-fibrotic disease.

• Clinical Implications: It explains why anti-IL-17 therapies failed (IL-17 is not the direct driver of fibrosis; LIGHT and metabolic reprogramming are). It suggests that targeting OXPHOS can overcome steroid resistance by killing the metabolic engine of pathogenic Th17 cells.
• Therapeutic Strategy: The paper proposes a dual-targeting strategy (OXPHOS inhibitor + LIGHT antagonist) as a promising clinical intervention for severe MGA and potentially other Th17-driven fibrotic conditions.
• Paradigm Shift: It positions severe asthma within the spectrum of "fibrotic diseases," necessitating anti-fibrotic rather than just anti-inflammatory approaches for the most severe endotypes.

In conclusion, the authors demonstrate that metabolic reprogramming (OXPHOS) sustains pathogenic Th17 cells, which secrete LIGHT to drive MMP9-mediated fibrosis. Disrupting this axis via dual blockade offers a potential cure for currently untreatable severe asthma.